https://seekingalpha.com/news/4060267-teva-earnings-preview-israeli-drugmaker-to-report-early-wednesday?source=feed_tag_israel
Jan 30, 2024 - Teva Pharmaceutical Industries (TEVA) is expected to report higher Q4 earnings before market open on Wednesday, with investors looking to see if the Israeli dru
0
sa:-7030372769802471236
0
https://seekingalpha.com/news/4060502-teva-to-divest-api-unit-to-focus-on-core-business-strengths?source=feed_tag_israel
Jan 31, 2024 - Teva plans to divest its API business as part of its growth strategy, aiming to focus on core strengths and capitalize on opportunities in the global API...
0
sa:-7662871080101055293
0
https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707
Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
zc:-9059281189219125428
0
https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel
Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here.
0
sa:-4863738783062410472
0
https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel
Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here.
0
sa:-5347432490541576242
0
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
zc:-2740657310709623932
0
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
zc:-5021796422199526666
0